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ABSTRACT Developmental commitment involves activa-
tion of lineage-specific genes, stabilization of a lineage-
specific gene expression program, and permanent inhibition
of inappropriate characteristics. To determine how these
processes are coordinated in early T cell development, the
expression of T and B lineage-specific genes was assessed in
staged subsets of immature thymocytes. T lineage character-
istics are acquired sequentially, with germ-line T cell antigen
receptor-b transcripts detected very early, followed by CD3«
and terminal deoxynucleotidyl transferase, then pTa, and
finally RAG1. Only RAG1 expression coincides with commit-
ment. Thus, much T lineage gene expression precedes com-
mitment and does not depend on it. Early in the course of
commitment to the T lineage, thymocytes lose the ability to
develop into B cells. To understand how this occurs, we also
examined expression of well defined B lineage-specific genes.
Although l5 and Ig-a are not expressed, the m0 and Im
transcripts from the unrearranged IgH locus are expressed
early, in distinct patterns, then repressed just before RAG1
expression. By contrast, RNA encoding the B cell receptor
component Ig-b was found to be transcribed in all immature
thymocyte subpopulations and throughout most thymocyte
differentiation. Ig-b expression is down-regulated only during
positive selection of CD41CD8– cells. Thus several key par-
ticipants in the B cell developmental program are expressed
in non-B lineage-committed cells, and one is maintained even
through commitment to an alternative lineage, and repressed
only after extensive T lineage differentiation. The results show
that transcriptional activation of ‘‘lymphocyte-specific’’ genes
can occur in uncommitted precursors, and that T lineage
commitment is a composite of distinct positive and negative
regulatory events.
In the mammalian hematopoietic system, cells differentiating
from the same precursor can adopt any of multiple distinct
developmental fates. Choice of a developmental lineage in-
volves the activation of lineage-appropriate genes and the
repression, or blocking of induction, of inappropriate genes.
Many specific genes have been identified that characterize
particular hematopoietic cell types, and the expression of these
genes has begun to provide useful landmarks for hematolym-
phoid differentiation (1–10). However, the mechanism of
lineage specification and the ‘‘commitment’’ events that make
it irreversible still are not well understood at the level of the
control of lineage-specific gene expression. One major ques-
tion is whether ‘‘master switch’’ events exist, in which cellular
identity is established by turning on a set of lineage-specific
genes coordinately. Another major question is whether cells
can activate such lineage-specific genes, yet still keep the
option of following other developmental pathways. These
unanswered questions cast shadows over attempts to infer the
timing and mechanism of developmental commitment from
the timing of activation of particular lineage-specific genes.
To address these issues we have focused on early murine T
cell differentiation. In this system there are substantial data to
establish a succession of lineage-restriction events, when de-
velopmental potential is narrowed, and to define their timing
relative to defined phenotypic changes (11, 12). We have used
this system to investigate, first, which T cell-specific genes are
activated at key stages of commitment, and second, when the
cells lose the ability to express ‘‘inappropriate’’ genes. Our
results show that T lineage genes are activated noncoordi-
nately, that many of these genes are activated before commit-
ment, that at least one B lineage gene is also activated during
T lineage differentiation, and that repression of such inappro-
priate genes can occur long after the cells are committed.
MATERIALS AND METHODS
Cell Preparation and Reverse Transcriptase–PCR (RT-
PCR) Conditions. All thymocytes were obtained from animals
between 3.5 and 5.5 weeks old and stained as described (13).
Stained cells, 5–20 3 104 per selected population, were sorted
into chilled tubes containing Hanks’ balanced salt solution
without phenol red, with 0.25% BSA, 5% fetal bovine serum,
and azide. A portion of each sorted sample was reserved for
reanalysis, and the rest of the cells were spun down, carrier
tRNA was added, and first-strand cDNA was synthesized from
each sample in a 40-ml reaction as described (13).
Primer pairs and annealing temperatures for the RT-PCRs
were taken from the following references: HPRT (14);
RAG-1, Ig-a, l5, and terminal deoxynucleotidyltransferase
(TdT) (1); CD3« (15); T cell antigen receptor-Cb (TCR-Cb)
(16); pTa (17); Im (18); m0 and Ig-b (7). All amplification
products cross an exon boundary. Different sample inputs
were normalized to obtain matched signals with hypoxanthine
phosphoribosyltransferase primers at a limiting number of
cycles. Amplification was for 29–35 cycles (usually 35) in the
experiments shown, and each lane shows the product amplified
from '1% of the cells in the initial sample. Repeated analyses
with various primers at lower and higher PCR cycle numbers
were routinely used to verify relative levels of expression in
different populations. The identity of the Ig-b PCR product
(nucleotides 194–688), was confirmed by hybridization with an
end-labeled internal oligonucleotide (nucleotides 571–591).
Hybridization (at 20–25 cycles) was quantitated by Phosphor-
Imager (Molecular Dynamics).
Fetal Liver and Spleen Cell Fractionation. C57BLy6 fetal
liver samples were obtained at E14.5 and stained with anti-
bodies against B220 (CD45R, RA3–6B2), Sca-1 (Ly-6A, E13–
161.7), and Gr-1 (Ly-6G, RB6–8C5), all from PharMingen.
Preparative cell sorting with three-color flow cytometry was
used to enrich four populations: (i) the B2202 Sca-12 Gr-12
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majority population ('92% of the population was in triple
negative quadrants; 66% within sorting gate); (ii) the B2201
Sca-11 Gr-12 population (0.4% of cells); (iii) the B2202
Sca-11 Gr-12 population (1.0%); and (iv) the Sca-12 Gr-11
population (2.5%). T enriched splenocytes were obtained by
magnetic cell sorting with streptavidin magnetic beads
(MACS, Miltenyi Biotec) and biotinylated antibodies against
B220, Gr-1, and Ter-119 (PharMingen) to deplete cells of
other lineages. CD41 and CD81 subsets, obtained from the T
enriched cells by fluorescence-activated cell sorting, were each
.98.5% pure.
Fractionation of Thymocytes Undergoing Positive Selection.
C57BLy6-Tlaa. thymocytes were stained, after Fc receptor
blocking, with phycoerythrin-conjugated anti-CD4 (Becton
Dickinson Labware), biotin conjugated anti-CD8 (Becton
Dickinson Labware), and Streptavidin-RED670 (Life Tech-
nologies, Gaithersburg, MD), as well as fluorescein isothio-
cyanate antibodies against either HSA (sort 1) (CD24, PharM-
ingen) or CD69 (sort 2) (PharMingen). Sorting gates are shown
in Fig. 4 (sort 1, B; sort 2, C). Cells were sorted by using single
or double two-color gates depending on the markers used.
Only the CD41 CD81 CD691 population showed significant
(.7%) contamination with other populations upon reanalysis.
RESULTS
Ordered Induction of T Lineage Genes Before Lineage
Commitment. Expression of both lineage-appropriate and
lineage-inappropriate genes was monitored by RT-PCR anal-
ysis of RNA from defined subsets of immature thymocytes. To
obtain the cells in high enrichment, in most cases the starting
thymocyte populations were taken from immunodeficient
scidyscid and RAG22y2 mice and sorted by multiparameter
flow cytometry, as described in detail (13). The developmental
potentials of the equivalent populations of normal thymocytes
have been studied extensively by cell transfer and in vitro
culture approaches (reviewed in refs. 11 and 12), and all
interpretations in this report of their relative progress toward
T lineage commitment are based on that body of work. Three
main populations were examined, as shown in Fig. 1: HSA1
Sca-11 CD251 CD441y2 c-kit1y2cells (‘‘HSA1’’), which in-
clude cells that would normally be undergoing TCR gene
rearrangement (populations C and D); HSAlow Sca-11 CD252
CD44high c-kit1 cells (‘‘HSA2 Sca-11’’), which are partially
CD4low and resemble stem cells (population A); and HSAlow
Sca-12 CD252 CD44high c-kit1 cells (‘‘HSA2 Sca-12 ’’), which
resemble immature NK cells (population B) (13, 19) (H.W.,
R.A.D., J. A. Yang-Snyder, and E.V.R., unpublished results).
To control for biological variation, all conclusions are based on
parallel analyses of corresponding subpopulations from dif-
ferent strains of scidyscid mice and from RAG22y2 mice.
Fig. 2 shows that T lineage genes begin to be expressed
noncoordinately in these cell types. RAG1 RNA was expressed
only in the HSA1 subpopulations (Fig. 2A), as expected
because only at this stage does TCR gene rearrangement
normally begin (20). Expression of CD3« and TdT begins
earlier, because these were observed in HSA1 cells and, at
lower levels, in the HSA2 Sca-11 cells (Fig. 2 A and B).
Another T lineage-specific gene, pTa, showed an onset of
expression intermediate between those of CD3« and TdT and
that of RAG1 (data not shown). However, germ-line tran-
scripts from the TCRb constant region were observed at
similar levels in all thymocyte populations (in these mutant
cells even the HSA1 stages must use the germ-line configu-
FIG. 1. Summary of immature cell populations in the immunodeficient mouse thymus and their developmental relationships. Bold type indicates
the names of subsets of cells analyzed in this paper. The extended profiles of phenotypic markers are from refs. 13 and 28 and H.W., R.A.D., and
E.V.R., unpublished results. Italic designations A–D key these populations to the samples studied in Fig. 2. Cell fates and developmental relationships
among populations A through D are based on work by others using the corresponding populations from normal adult thymus, in which populations
A and B are not separated (11, 12). The CD441 CD251 subset of HSA1 cells (population C) has lost the potential to give rise to B or NK cells,
although it retains the ability to give rise to dendritic cells (not shown). Cells beyond this stage (e.g., population D) are fully T lineage committed.
The possibility that the NK-like cells (population B) can give rise to T cells as well as NK cells is based on the properties of a similar subset in
fetal thymus (51–53). The CD41 subset, which has been studied extensively in normal thymus, includes a subset of population A plus some of the
transitional cells between A and C that have not yet acquired CD25 (H.W., R.A.D., and E.V.R., unpublished results).
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ration for expression, so only TCRb enhancer activity is
relevant). TCR-Cb transcripts also were the only T cell-specific
genes detectable in fractions from normal E14.5 fetal liver, as
shown in Fig. 2B. TCR-Cb transcripts were expressed both in
a fetal liver fraction enriched for B, T, and NK progenitors
(fraction ‘‘L,’’ Sca-11 B2201 Gr-12; Fig. 2B, lane 6) (21–24)
and in a stem cell-enriched fraction (fraction ‘‘S,’’ Sca-11
B2202 Gr-12) (Fig. 2B, lane 7). Some RAG1 expression also
was seen in the fetal liver ‘‘L’’ fraction (Fig. 2A, lane 11), but
this appears to be because of B lineage precursors therein. The
lack of any CD3« expression in these populations shows that
T lineage differentiation in E14.5 fetal liver does not proceed
even to the level of the earliest thymocytes.
These results suggest that TCRb germ-line transcription is
activated first in lymphoid precursors, followed by CD3« and
TdT, then pTa, and last by induction of RAG1. The expression
of pTa and TdT seems to be excluded or down-regulated in the
NK-like HSA2 Sca-12 population (‘‘B’’), and RAG1 expres-
sion is induced only in those cells that have reached the HSA1
stage (‘‘CyD’’). Some expression is precocious: at least two T
lineage-specific genes, TCRb and CD3«, clearly begin to be
expressed before the stages (CD251 CD441y2; here, popula-
tion ‘‘C’’ in the HSA1 fraction) when the population is
committed to give rise to T cells (25–28).
Selective Ectopic Expression of a B Lineage Gene. B cell
developmental potential is reported to persist in the “CD4low”
class of immature thymocytes (25, 26, 28), which consists of
cells in a continuum from the HSA2 Sca-11 fraction to the
HSA1 fraction (29) (H.W., unpublished results; see Fig. 1).
However, the B cell genes l5 and Ig-a (mB-1, CD79a), which
were detected readily in the Sca-11 B2201 fetal liver fraction,
were undetectable in most of the thymocyte subsets (Fig. 2 A).
A slight signal for Ig-a expression was observed only in the
minor, poorly characterized HSA1 Sca-12 fraction (data not
shown), possibly because of the presence of a minor population
of thymic B cell precursors (30). The absence of Ig-a and l5
expression initially suggested that the highly immature HSA2
Sca-11 thymocytes (population ‘‘A’’) do not express any B
lineage genes, even though they may be competent to undergo
B lineage differentiation. However, as representatives of even
earlier B lineage genes (1, 7, 18), expression of the germ-line
IgH transcripts m0 and Im and of Ig-b (B29, CD79b) was also
monitored (Fig. 2 A). The primer pairs used for Ig-b detect the
full-length mRNA, not the deleted form (31, 32).
Unlike Ig-a and l5, these three transcripts were detected in
thymocytes, describing distinct patterns of expression. The m0
amplification product was generated only from the most im-
mature, HSA2 Sca-11 cells (‘‘A’’), whereas the Im product
(generally considered B lineage-specific) was found in both
subsets of HSA2 cells (‘‘A’’ and ‘‘B’’). Both of these transcripts,
however, were shut off during the transition from HSA2 to
HSA1 (Fig. 2 A and data not shown). Thus, the germ-line
transcription of the IgH locus does initiate in thymocytes, but
is repressed during or before the induction of RAG1. Like
these transcripts, Ig-b was also found to be expressed in the
HSA2 Sca-11 thymocytes (Fig. 2 A). Unexpectedly, however,
Ig-b was also found in the more advanced HSA1 thymocytes
(populations ‘‘C’’ and ‘‘D’’), which correspond in phenotype
(CD441y2 CD251) to normal immature thymocytes that have
completely lost any B cell developmental potential (25, 26, 28).
Only the HSA2 Sca-12 thymocytes (‘‘B’’) expressed this gene
at lower levels.
Ig-b initially was reported to be expressed only in B lineage
cells, and absent from thymocytes, by the criterion of slot-blot
hybridization (33). To confirm that genuine Ig-b was being
detected with our primers, normal adult tissues were tested to
verify specificity of expression (Fig. 3), and the PCR products
were hybridized with a third, labeled oligonucleotide repre-
senting an internal Ig-b sequence (Fig. 3B). Although expres-
sion was abundant in normal spleen (Fig. 3A, lanes 3 and 6),
no product could be amplified from skeletal muscle cDNA
(lane 1; '102 3 less, by hybridization), and much less Ig-b
could be detected in cDNA from T enriched normal spleen
cells (Fig. 3A, lane 2; Fig. 3B, lane 3). In pure populations of
T cells isolated by fluorescence-activated cell sorting (Fig. 3B,
lanes 1 and 2), only very low levels of Ig-b RNA were detected
in the CD81 population (lane 2) and even less was detected in
the CD41 population (lane 1). When monitored by hybridiza-
tion at low numbers of PCR cycles, Ig-b RNA indeed was
undetectable in these T cells (Fig. 3B Bottom). By contrast, the
m0 and Im transcripts from the germ-line IgH locus were readily
detected in mature T cells (Fig. 3B and data not shown). Thus,
our results support the identification of Ig-b as highly ‘‘B
lineage-specific’’ at the level of mature cells.
FIG. 2. Expression of early T cell genes in immature thymocytes
and normal fetal liver cells. RT-PCR was performed with the indicated
primers to compare subsets of cells from immunodeficient mouse
thymocytes with subsets from wild-type C57BLy6 fetal liver. All
samples presented in one lane were derived from equal aliquots of the
same cDNA sample. Subpopulations analyzed in each lane are indi-
cated by the letters under each sample. For thymocyte subsets: U,
unfractionated; A, HSA–Sca-11; B, HSA– Sca-1–; CyD, HSA1 (Sca-
11). For fetal liver subsets: T, total; N, B2202 Sca-12 Gr-12 (triple
negative); L, B2201 Sca-11 Gr-12 (lymphoid-enriched); S, B2202
Sca-11 Gr-12 (stem cell enriched); G, Sca-12 Gr-11 cells. (A) Lanes:
1–4, RAG22y2 thymus; 5–8, C.B 17-scidyscid thymus; 9–13, C57BLy6
fetal liver subsets. (B) Lanes: 1–4, B6-scidyscid thymus; 5–8, C57BLy6
fetal liver. RAG1 levels are higher in RAG-22y2 thymocytes than in
SCID thymocytes because the former survive longer after the induc-
tion of recombinase expression (13). TdT is expressed only during
postnatal lymphocyte development.
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By contrast, unfractionated normal thymus populations
with no significant B lineage contamination showed at least
as much Ig-b expression as immunodeficient thymus popu-
lations (Fig. 3A, lanes 4 and 5). Although there are non-T
lineage and primitive cells in scid or RAG2 thymus that
might express Ig-b, these are diluted '1003 in normal
thymus. Thus, this result rules out the possibility that thymic
Ig-b expression is restricted to a rare early or non-T lineage
thymocyte type. The level of this expression in unfraction-
ated normal thymus remains $93 lower than in spleen (data
not shown), explaining the lack of detection using other
methods. Even so, Ig-b RNA continues to be expressed in
cells before and after TCR surface expression, and in
thymocytes of both TCR-ab and TCR-gd lineages, as shown
by the similar levels of Ig-b RNA per cell in thymocytes from
normal, TCRb2y2, TCRd2y2, and TCRb2y2 d2y2 mice
(data not shown). Thus, although mature T cells express little
if any Ig-b, the ongoing transcription of this B cell gene
appears to be a common and persistent feature of diverse
classes of thymocytes.
Delayed Repression: Shutoff of Ig-b Expression During
Positive Selection. To ascertain whether Ig-b expression might
be turned off at any stage of thymic development, normal
C57BLy6 thymocytes were fractionated to separate cells
through different stages of positive selection and then analyzed
for RNA expression (Fig. 4). Two different sorting strategies
were used to separate postselection intermediates between the
CD41 CD81 stage and the CD41 CD82 stage: one on the basis
of CD8 and HSA expression, and another on the basis of CD8
and CD69 expression. As shown in Fig. 4, CD3« expression
levels were similar in all populations, as expected, and RAG1
expression declined sharply at the CD41 CD8int HSA1 CD691
stage, in agreement with previous reports that this gene is
turned off rapidly in response to TCR-mediated selection
signals (34–36). Ig-b RNA was not confined to the earliest
CD42 CD82 cells: it was expressed comparably in all stages
through postselection RAG1 down-regulation, and only re-
duced in the CD41 CD82 single positive stages (Fig. 4). This
expression pattern was confirmed by hybridization with an
internal oligonucleotide probe (Fig. 4 D and E, lowermost
panel). Ig-b expression appeared to persist even longer in
CD42 CD81 thymocytes, in agreement with its continued
detectable expression in CD81 peripheral T cells. Thus, the
expression of Ig-b RNA persists in thymocyte differentiation
at least until after the cells begin to undergo positive selection
to the CD41 lineage. Only at this late stage is Ig-b transcription
shut off.
FIG. 3. Preferential expression of Ig-b (B29) in populations con-
taining B cells and thymocytes. (A) Analysis of Ig-b RNA expression
in different tissues. Lanes: 1, skeletal muscle; 2, T enriched spleen
(.93% T cells); 3 and 6, normal mouse splenocytes ($60% B cells; 4,
total C57BLy6-scidyscid thymocytes; 5, normal C57BLy6 thymocytes.
(B) Comparison of Ig-b and Im expression in subsets of normal mouse
splenic T cells and B cells. T cell subsets were purified as described in
Materials and Methods. Samples without reverse transcriptase gave no
signal (data not shown). (Top) Products of 33 PCR cycles detected by
ethidium bromide staining. (Bottom) Products of 24 PCR cycles
detected by hybridization. Lanes: 1, CD41 T cells; 2, CD81 T cells; 3,
T enriched spleen; 4, total spleen; 5, B2201 B enriched cells.
FIG. 4. Shutoff of Ig-b expression at a late stage in the positive
selection of CD41 CD82 thymocytes. (A) Summary of phenotypic
changes accompanying positive selection. (B and C) Three-color flow
cytometry of normal C57BLy6 thymocytes stained for CD4, CD8, and
HSA expression (B) or for CD4, CD8, and CD69 expression (C). The
sorting gates used in the two sorting experiments to dissect positive
selection stages are indicated, as described in Materials and Methods.
(D and E) RT-PCR analyses of RNA levels in the populations
fractionated from the stained samples in B (D) and in C (E). Also
shown (bottom row, D and E) are autoradiograms of the hybridization
of an internal probe to the Ig-b PCR products from these samples.
Note that in E, the samples in lanes 5 (CD41 CD82 CD692) and 6
(CD41 CD82 CD691) are reversed with respect to their order in
development.
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DISCUSSION
We have sought to define the progressive narrowing of devel-
opmental potential and the lineage commitment that occur
during thymocyte differentiation (11, 12, 25–28) in terms of
discrete changes in gene expression. Our results show that T
lineage specification and commitment actually involve a cas-
cade of staggered gene regulatory events, not a single clean
transition.
The activation of different T lineage “specific” genes begins
asynchronously, with several of these genes turned on at stages
that apparently precede T lineage commitment. Our data
generally agree with previous results on the expression of
particular genes in early thymocytes (37–41), but the different
onsets of expression of these genes are more sharply defined
here than in previous studies. This is largely because of the
sensitivity of RT-PCR, the simplified isolation of early subsets
from immunodeficient thymocyte populations (13), our sep-
aration of the NK-like Sca-12 HSA2 (CD42) cells from the
precursor-like Sca-11 HSA2 (CD41y2) cells within the CD441
CD252 thymocyte population, and our emphasis on direct,
semiquantitative comparison among different T lineage genes.
The results imply that some ‘‘T cell-specific’’ genes are initially
activated in cells that may never give rise to T cells. Such genes
therefore cannot require the action of any ‘‘master regulator’’
factor powerful enough to impose T lineage commitment.
Although such a dominant master regulator, if it existed, could
participate in later aspects of T lineage gene expression, it
could not be required for the initial transcription of RNAs such
as CD3« or TCR-Cb (unrearranged) transcripts.
Control of gene expression through this process is initially
lineage-nonspecific, in that two transcripts controlled by the
Ig-Em enhancer also begin to be expressed in immature
thymocytes. These transcripts are down-regulated just before
the induction of recombinase activity, indicating a pro-
grammed, stage-specific repression mechanism. The role of
this repression is underlined by the fact that mature T cells,
which no longer express recombinase, appear to resume free
expression of these two transcripts, in agreement with an
extensive body of evidence for the activity of the Em enhancer
in later-stage thymocytes and mature T cells. The implication
is that negative regulators, not positive regulators dependent
on prior lineage commitment, may restrict IgH transcription
specifically during one critical period when recombinase must
choose between Ig and TCR gene targets.
This developmental gene expression program is still leaky
enough to allow the sustained transcription of Ig-b until late
stages of thymocyte maturation. There are other cases of
apparent interlineage sharing of lymphocyte molecules, such
as the expression of CD3 in fetal NK cells (42), but this case
adds emphasis to the phenomenon in several ways. The T and
B lineage programs are more distinct than the NK and T
lineages, yet thymocytes do not repress Ig-b until they have
progressed far down this well marked developmental pathway,
with any chance to differentiate as B cells left far behind. Also,
unlike other, poorly characterized markers shared by B cells
and thymocytes, e.g., ThB and HSA itself, Ig-b protein is a
critical, cell-type-specific component of the B cell antigen
receptor, which acts in early B cell precursors to trigger the
initiation of V-DJh Ig gene rearrangements (43). There is still
a question of whether Ig-b is really B lineage-specific (note
some expression of Ig-b in a heterogeneous, Gr-11 subset of
fetal liver cells, Fig. 2A). Nevertheless, it achieves a highly
B-specific pattern of expression in mature cells. Also, although
Ig-b is one of the few B lineage genes that continues to be
expressed in fetal liver cells of E2A knockout mice (44), it
appears to depend on B lineage-specific transcription factors,
because it is not expressed in the developmentally arrested
B2201 marrow cells of EBF knockout mice (3). Thus, its
expression has been viewed as an early, positive marker of B
lineage specification or commitment. However, our data show
that late T lineage-specific repression, not a requirement for B
lineage-specific activating factors, restricts expression of this
gene in T cells.
The permissiveness of thymocytes for expression of the
‘‘early’’ B cell gene, Ig-b, contrasts with their lack of expression
of the slightly ‘‘later’’ B cell genes, Ig-a and l5. This suggests
that some positive transcription factors needed to drive ex-
pression of these ‘‘late’’ genes are excluded by T lineage
differentiation, even though the factors that drive expression
of Ig-b are not. Whatever the mechanism, this exclusion is
temporally and mechanistically separate from the event in
which the ‘‘inappropriate’’ Ig-b gene expression is repressed,
later in differentiation. Thus, diverse negative as well as
positive regulatory mechanisms are required.
Even if the Ig-b transcription does not result in any protein
product, it is a valuable indicator of ‘‘upstream’’ regulatory
events in thymocytes. The separate issue of whether low-level
expression of Ig-b RNA confers any positive function on
thymocytes remains to be determined. At a crude steady-state
level, it is clear that major thymocyte populations are un-
changed in Ig-b knockout mice (43). On the other hand, if the
Ig-b were expressed at the protein level, there is evidence that
it could interact strongly with the CD3 complexes that are also
present in thymocytes at early stages (45). It is conceivable that
such hybrid complexes could play a role in pre-T cell receptor
function or the establishment of signaling thresholds for
viability (46, 47).
To prove a strict correlation between the regulation of
various genes in the earliest stages of T cell differentiation and
the establishment of developmental commitment, we will need
to use single-cell methods. However, our present findings
already show that the induction of genes associated with one
lineage need not be rigidly linked with repression of genes
associated with other potential lineages. Moreover, cells can
make substantial progress activating T lineage-specific genes
before they lose developmental plasticity and undergo com-
mitment. At least some of this precocious expression appears
to be multilineage. There are precedents for early multilineage
gene expression, followed by lineage-specific repression, in
erythromyeloid precursors (48, 49). Other hematopoietic pre-
cursors provide evidence for transdifferentiation (50). Now in
the lymphoid case as well, both positive and negative gene
regulatory mechanisms can be seen to contribute to lineage
specificity, acting at different times. The stage is set now for
identification of the lineage-specific transcription factors that
are targets and executors of these mechanisms.
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